Cell Source Inc. (CLCS) 0.9000 $CLCS
Cell Source to Present at Rodman & Renshaw Global Investment Conference in New York City on September 10, 2014
PR Newswire - Wed Sep 03, 12:52PM CDT
Cell Source, Inc. (OTCQB: CLCS) ("Cell Source"

an immunotherapy and regenerative medicine company, announced today its President and CEO, Itamar Shimrat, will present at the Rodman & Renshaw 16th Annual Global Investment Conference which will take place at the New York Palace Hotel in New York City on September 8th through 10th, 2014. Mr. Shimrat is scheduled to present at 9.35 am on Wednesday, September 10th.
Cell Source Inc. Announces Acquisition and $3.6 Million Private Placement to Advance Novel Cancer Therapies
PR Newswire - Tue Jul 01, 12:30PM CDT
Cell Source, Inc. (OTCQB: CLCS) ("Cell Source"

today announced the successful acquisition (the "Acquisition"

, through a share exchange agreement, of all of the outstanding shares of Cell Source (Israel) Ltd., a pre-clinical cell therapy development company with a focus on the facilitation of safer and more accessible bone marrow and organ transplants and effective treatment of blood cell cancers (e.g., leukemia, lymphoma). Prior to the Acquisition, Cell Source Ltd. completed a private placement consisting of approximately 4.8 million units of its securities, for total gross proceeds of approximately $3.6 million. Each unit consisted of one share of common stock and one common stock purchase warrant. Sichenzia Ross Friedman Ference LLP (www.SRFF.com) acted as legal counsel to Cell Source (Israel) Ltd. in the private placement and Acquisition.